Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019)

Champions Oncology (CSBR) has 2 years of Non-Current Deffered Revenue data on record, last reported at $851000.0 in Q2 2019.

  • For Q2 2019, Non-Current Deffered Revenue rose 87.44% year-over-year to $851000.0; the TTM value through Apr 2019 reached $851000.0, up 87.44%, while the annual FY2019 figure was $851000.0, 87.44% up from the prior year.
  • Non-Current Deffered Revenue reached $851000.0 in Q2 2019 per CSBR's latest filing, up from $733000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $851000.0 in Q2 2019 and bottomed at $454000.0 in Q2 2018.